Seres Therapeutics (MCRB) Gains from Investment Securities: 2015-2025
Historic Gains from Investment Securities for Seres Therapeutics (MCRB) over the last 8 years, with Mar 2025 value amounting to $1.2 million.
- Seres Therapeutics' Gains from Investment Securities rose 399.15% to $1.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.2 million, marking a year-over-year decrease of 52.68%. This contributed to the annual value of $17.7 million for FY2024, which is 19.38% up from last year.
- Per Seres Therapeutics' latest filing, its Gains from Investment Securities stood at $1.2 million for Q1 2025, which was up 1,057.30% from -$130,000 recorded in Q2 2024.
- Over the past 5 years, Seres Therapeutics' Gains from Investment Securities peaked at $87.0 million during Q4 2022, and registered a low of -$416,000 during Q1 2024.
- In the last 3 years, Seres Therapeutics' Gains from Investment Securities had a median value of $617,500 in 2023 and averaged $624,081.
- In the last 5 years, Seres Therapeutics' Gains from Investment Securities skyrocketed by 1,044.84% in 2022 and then plummeted by 110.74% in 2024.
- Seres Therapeutics' Gains from Investment Securities (Quarterly) stood at $7.6 million in 2021, then surged by 1,044.84% to $87.0 million in 2022, then tumbled by 97.92% to $1.8 million in 2023, then tumbled by 110.74% to -$130,000 in 2024, then skyrocketed by 399.15% to $1.2 million in 2025.
- Its Gains from Investment Securities stands at $1.2 million for Q1 2025, versus -$130,000 for Q2 2024 and -$416,000 for Q1 2024.